Aktienanalyse zu Legend Biotech Corp (LEGN)LEGNLegend Biotech Corp

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Legend Biotech Corp is currently trading at $18.62, which is significantly below the analyst price targets ranging from $33 to $74, indicating potential upside. However, the stock has a low RSI of 43.93, suggesting it is nearing oversold conditions, but it also reflects a lack of strong momentum. The company reported a profit of $33.2 million in Q2 2026, a notable improvement from a loss of $125.4 million in the same quarter last year, indicating a positive trend in financial performance. The main risk is the forward P/E ratio of 27.55, which suggests that the stock may be overvalued relative to its earnings potential, especially given the recent downgrades from analysts.